Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma

Annals of Oncology

Volumn 8, Issue SUPPL. 1, 1997, Pages

  De Wit, M ^a   Bumann, D ^a   Beyer, W ^a   Herbst, K ^a   Clausen, M ^a   Hossfeld, D K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

18 fluorodeoxyglucose (FDG); lymphoma; positron emission tomography; residual mass

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONFERENCE PAPER; HODGKIN DISEASE; HUMAN; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

EID: 0030978419     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/8.suppl_1.s57     Document Type: Conference Paper

References (31)

1. DeVita VR, Hellman S, Jaffe ES. Hodgkin's disease. In DeVita VR Jr. Hellman S, Rosenberg SA (eds): Cancer, 4th ed. Philadelphia: 1993: 1819-59.
2. DeLongo DL, DeVita VR, Jaffe ES et al. Lymphocytic lymphomas. In DeVita VR Jr, Hellman S, Rosenberg SA (eds): Cancer, 4th ed. Philadelphia 1993; 1859-928.
3. Radford JA et al. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease. J Clin Oncol 1988; 6: 940.
4. Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med 1993; 32: 623-48.
5. Newman JS, Francis IR, Kaminski MS et al. Imaging of lymphoma with PET with 2-(F-18)-Fluoro-2-deoxy-D-glucose: Correlation with CT. Radiology 1994; 190: 111-6.
6. Tse N, Hoh C, Rosen P et al. Whole body PET/FDG imaging in Hodgkin's disease and non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1994; 13: 378 (Abstr).
7. De Wit M, Beyer W, Hotze LA et al. Positron emission tomography (PET) using 18-FDG for staging in lymphomas - preliminary results. Onkologie 1995; 18 (Suppl 2): 74 (Abstr).
8. Barrington SF, Carr R. Staging of Burkitt's lymphoma and response to treatment monitored by PET scanning. Clin Oncol R Coll Radiol 1995; 7: 334-5.
9. Weber G. Enzymology of cancer cells. Pt. 2. N Engl J Med 1977; 296: 541-51.
10. Gallagher BM, Fowler JS, Gutterson NI et al. Metabolic trapping as a principle of radiopharmaceutical design: Some factors responsible for the biodistribution of [F-18]2-deoxy-2-fluoro-D-glucose. J Nucl Med 1978; 19: 1154-61.
11. Zasadny KR, Wahl RL. Enhanced FDG-tumor imaging with correlation-coefficient filtered influx-constant images. J Nucl Med 1996; 37: 371-4.
12. Libson E, Polliack A, Bloom RA. Value of lymphangiography in the staging of Hodgkin's lymphoma. Radiology 1994; 193: 757-9.
13. Gerrits CJ, van Overhagen H, van Lom K et al. Ultrasound examination of pathological cervical lymphnodes in patients with non-Hodgkin's lymphoma and Hodgkin's disease. Br J Haematol 1994; 88: 626-8.
14. Hoane BR, Shields AF, Porter BA et al. Comparison of initial lymphoma staging using computed tomography (CT) and magnetic resonance (MR) imaging. Am J Hematol 1994; 47: 100-5.
15. Samoszuk MK, Anderson AL, Ramzi E et al. Radioimmunodetection of Hodgkin's disease and non-Hodgkin's lymphomas with monoclonal antibody to eosinophil peroxidase. J Nucl Med 1993; 34: 1246-53.
16. Da Costa L, Carde P, Lumbroso JD et al. Immunoscintigraphy in Hodgkin's disease and anaplastic large cell lymphomas: Results in 18 patients using the iodine radiolabeled monoclonal antibody HRS-3. Ann Oncol 1992; 3 (Suppl 4): 53-7.
17. Blend MJ, Hyun H, Kozloff M et al. Improved staging of B-cell non-Hodgkin's lymphoma patients with 99mTc-labeled LL2 monoclonal antibody fragment. Cancer Res 1995; 55 (Suppl 23): 5764-70s.
18. Baum RP, Niesen A, Hertel A et al. Initial clinical results with technetium-99m-labelled LL2 monoclonal antibody fragment in the radioimmunodetection of B-cell lymphomas. Cancer 1994; 73 (Suppl 3): 896-9.
19. Goldsmith SJ, Macapinlac HA, O'Brien JP. Somatostatin-receptor imaging in lymphoma. Semin Nucl Med 1995; 25: 262-71.
20. Wylie BR, Southeer AE, Joshua DE et al. Gallium scanning in the management of mediastinal Hodgkin's disease. Eur J Haematol 1989; 49: 344-7.
21. Sandrock D, Lastoria S, Magrath IT et al. The role of gallium-67 tumour scintigraphy in patients with small, non cleaved cell lymphoma. Eur J Nucl Med 1993; 20: 119-22.
22. Anderson KC, Leonhard RCF, Canellos GP et al. High dose gallium imaging in lymphoma. Am J Nucl Med 1983; 75: 327-31.
23. Brice P, Rain JD, Frija J et al. Residual mediastinal mass in malignant lymphoma: Value of magnetic resonance imaging and gallium scan. Nouv Rev Fr Hematol 1993; 35: 457-61.
24. Hill M, Cunningham D, Macvivar D et al. Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. J Clin Oncol 1993; 11: 2273-8.
25. Israel O, Front D, Betman L et al. Gallium-67-imaging in monitoring lymphoma response to treatment. Cancer 1988; 61: 2439-43.
26. Kostakoglu K, Yeh SDJ, Portlock C et al. Validation of gallium-67-citrate single photon computed tomography in biopsy confirmed residual Hodgkin's disease in the mediastinum. J Nucl Med 1992; 33: 345-50.
27. Becker WS, Behr TM, Cumme F et al. 67Ga citrate versus 99mTc-labeled LL2-Fab′ (anti-CD22) fragments in the staging of B-cell non-Hodgkin's lymphoma. Cancer Res 1995; 55 (Suppl 23): 5771-3s.
28. Zasadny KR, Wahl RL. Standardized uptake values of normal tissue at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: Variations with body weight and a method for correction. Radiology 1993; 189: 847-50.
29. Weber W, Römer S, Ziegler D et al. Clinical value of F-18-FDG PET in solitary pulmonary nodules. Eur J Nucl Med 1995; 22: 775 (Abstr).
30. Stollfuss J, Kocher F, Glatting S et al. 18-FDG PET and ERCP in the diagnosis of pancreatic cancer. Eur J Nucl Med 1995; 22: 826 (Abstr).
31. Lapela M, Grenman R, Kurki T et al. Head and neck cancer: Detection of recurrence with PET and 2-[F-18] Fluoro-2-deoxy-D-glucose. Radiology 1995; 197: 205-11.